Merck & Co. stock gains as FDA approves oral cholesterol drug and mRNA data lift outlook

Merck & Co. stock is trading near its recent highs after fresh Phase 3 mRNA cancer data and the first FDA-approved oral PCSK9 cholesterol drug sharpen the growth story. For investors, the mix of innovative launches, strong guidance and dividend income is key.

Merck & Co. stock (ISIN US58933Y1055) is trading around 149.09 USD as of September 1, 2026, with an intraday gain of about 0.9 percent on the New York Stock Exchange, according to MarketWatch data. As a secondary listing in Germany under ticker UJ9 on the Frankfurt venue, the share offers DACH investors direct access to the US pharma heavyweight.

Pipeline milestones support growth story

According to an analysis on Yahoo Finance dated September 2, 2026, Merck recently reported the first positive Phase 3 result from an individualized mRNA cancer vaccine trial in melanoma. The article notes that the companys narrative projects revenue of 74.9 billion USD and earnings of 22.0 billion USD by 2029, underlining managements confidence in medium term growth.

The same analysis highlights that these 74.9 billion USD in projected revenue for 2029 would represent a clear step up compared with historical sales levels, indicating a meaningful expansion of Mercks oncology and vaccines franchises if the pipeline delivers as planned. For investors, the combination of an mRNA platform and existing immuno oncology assets is a central pillar of the long term equity story.

First oral PCSK9 strengthens cardiovascular franchise

On September 2, 2026, specialist portal Simply Wall St reported that Merck has received US FDA approval for LIPFENDRA, described as the first oral PCSK9 inhibitor for cholesterol management, in an article on Merck winning FDA approval. PCSK9 inhibitors are a class of drugs that help lower LDL cholesterol, and an oral formulation can be more convenient than injectable therapies.

This first in class oral PCSK9 approval adds a new growth driver to Mercks cardiovascular portfolio and broadens its presence in chronic preventive therapies. Compared with injectable PCSK9 products that require regular injections, an oral daily tablet may increase patient adherence, potentially expanding the addressable market for cholesterol lowering treatment.

Dividend and valuation remain in focus

According to the press release overview on Yahoo Finance, Merck has announced a cash dividend of 0.85 USD per share with an ex dividend date of September 15, 2026. On an annualized basis, this corresponds to 3.40 USD per share, which offers an income component on top of the growth story for shareholders.

With the share price around 149.86 USD at the closing auction on September 1, 2026, also reported in the same overview, the annualized dividend of 3.40 USD per share translates into a dividend yield of about 2.3 percent. This places Merck in the group of large healthcare stocks that combine pipeline driven growth prospects with a steady cash return profile.

Key product: Keytruda as cornerstone of the portfolio

Beyond LIPFENDRA and the emerging mRNA programs, the anti PD 1 therapy Keytruda remains Mercks flagship product and the largest contributor to revenue. The medicine is approved in numerous cancer indications and forms the backbone of the companys oncology franchise. For many investors, the durability of Keytrudas cash flows and the ability to transition patients to next generation immuno oncology and mRNA based therapies is a central question.

Merck & Co. stock and trading perspective

Merck & Co. stock closed at 149.86 USD on the New York Stock Exchange on September 1, 2026, according to the press release overview on Yahoo Finance, and traded around 150.01 USD in premarket indications on September 2, 2026. This puts the share close to its recent highs and reflects investor confidence after the positive mRNA trial data and the FDA approval of an oral PCSK9 inhibitor.

Merck & Co. at a glance

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: MRK
• Trading venue: NYSE (primary); Frankfurt UJ9 (secondary)
• Price (as of September 1, 2026, 16:03): 149.86 USD
• Market capitalization: 378,000,000,000 USD (as of September 1, 2026)
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: S&P 500